ArticleNucleic acids research2014
Staphylococcus epidermidis Csm1 is a 3'-5' exonuclease.
Article in Nucleic acids research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- A pervasive RT-qPCR artifact inflates RNA knockdown by RNA-targeting CRISPR.Nature biotechnology · 2026Article
- A phage-encoded anti-CRISPR protein co-opts host enolase to prevent type III CRISPR immunity.Nature microbiology · 2025Article
- Bioinformatic analysis of type III CRISPR systems reveals key properties and new effector families.Nucleic acids research · 2024Article
- Structures of an active type III-A CRISPR effector complex.Structure (London, England : 1993) · 2022Article
- Structural and biochemical characterization of in vivo assembled Lactococcus lactis CRISPR-Csm complex.Communications biology · 2022Article
- Structural principles of CRISPR-Cas enzymes used in nucleic acid detection.Journal of structural biology · 2022Review
- SCOPE enables type III CRISPR-Cas diagnostics using flexible targeting and stringent CARF ribonuclease activation.Nature communications · 2021Article
- Structural organization of a Type III-A CRISPR effector subcomplex determined by X-ray crystallography and cryo-EM.Nucleic acids research · 2019Article
- The ribonuclease activity of Csm6 is required for anti-plasmid immunity by Type III-A CRISPR-Cas systems.RNA biology · 2019Article
- CRISPR-Based Technologies: Impact of RNA-Targeting Systems.Molecular cell · 2018Review
- Article
- Discovery of Oligonucleotide Signaling Mediated by CRISPR-Associated Polymerases Solves Two Puzzles but Leaves an Enigma.ACS chemical biology · 2018Article
- RNA and DNA Targeting by a Reconstituted Thermus thermophilus Type III-A CRISPR-Cas System.PloS one · 2017Article
- Programmable type III-A CRISPR-Cas DNA targeting modules.PloS one · 2017Article
- Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems.Science (New York, N.Y.) · 2016Review
- Multiple nucleic acid cleavage modes in divergent type III CRISPR systems.Nucleic acids research · 2016Article
- Harnessing Type I and Type III CRISPR-Cas systems for genome editing.Nucleic acids research · 2016Article
- Bipartite recognition of target RNAs activates DNA cleavage by the Type III-B CRISPR-Cas system.Genes & development · 2016Article
- RNA-activated DNA cleavage by the Type III-B CRISPR-Cas effector complex.Genes & development · 2016Article
- Primary processing of CRISPR RNA by the endonuclease Cas6 in Staphylococcus epidermidis.FEBS letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) offer an adaptive immune system that protects bacteria and archaea from nucleic acid invaders through an RNA-mediated nucleic acid cleavage mechanism. Our knowledge of nucleic acid cleavage mechanisms is limited to three examples of widely different ribonucleoprotein particles that target either DNA or RNA. Staphylococcus epidermidis belongs to the Type III-A CRISPR system and has been shown to interfere with invading DNA in vivo. The Type III-A CRISPR system is characterized by the presence of Csm1, a member of Cas10 family of proteins, that has a permuted histidine-aspartate domain and a nucleotidyl cyclase-like domain, both of which contain sequence features characteristic of nucleases. In this work, we show in vitro that a recombinant S. epidermidis Csm1 cleaves single-stranded DNA and RNA exonucleolytically in the 3'-5' direction. We further showed that both cleavage activities are divalent-metal-dependent and reside in the GGDD motif of the cyclase-like domain. Our data suggest that Csm1 may work in the context of an effector complex to degrade invading DNA and participate in CRISPR RNA maturation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.